Glaukos Stock: The Second J-Code Rewrites The Risk Math (NYSE:GKOS)
· seekingalpha.com
Glaukos (GKOS) Q2 sales +50% as iDose TR & Epioxa drive 85% gross margin; 2026 guide raised. Read here for a detailed investment analysis.
The majority of the Glaukos ( GKOS ) discussion today boils down to just this: what happens to iDose TR if five Medicare contractors finalize their proposed cov...